We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.72 | -0.56% | 128.50 | 129.93 | 127.80 | 129.43 | 5,895,651 | 23:28:51 |
From May 2022 to May 2024
By Sabela Ojea
Merck & Co. said Thursday that a West Virginia district court ruled in favor of the company in a two-patent infringement suit against Viatris Inc.
The company said that the case was related to the sitagliptin medication, which is mainly sold under the brand names Januvia and Janumet to treat type 2 diabetes.
The federal court found both Merck's patents involved on the case were valid and infringed, Merck said, noting that the decision is still subject to appeal.
Merck had filed infringement actions against Viatris under two patents, for which Viatris alleged non-infringement and, or invalidity, it said.
Viatris is seeking U.S. Food and Drug Administration approval to market generic versions of Januvia and Janumet in the U.S., Merck said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 22, 2022 07:23 ET (11:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
